Royal Philips and the Academic Medical Center in Amsterdam, the Netherlands, will collaborate in a European multicenter trial of a new diagnostic technique to assess the results of minimally invasive treatment for diabetic foot and critical limb ischemia. The trial is slated to start this summer with final results expected in 2017.
Eli Lilly has led a Series B round for San Diego, CA-based startup Companion Medical. The financing is expected to enable the completion of testing and 510(k) submission for its Bluetooth-enabled insulin pen and accompanying smartphone app. The amount of the financing was undisclosed.
Outset Medical got its Tablo all-in-one diabetes dialysis device cleared by FDA in November. Now investors, including existing backers Warburg Pincus and The Vertical Group, are ponying up $59.6 million to back marketing the device to dialysis clinics as well as to complete a pivotal trial for home use.
Chinese bidders are emerging in the long-sought sale of Bayer's diabetes device business, as the German giant seeks to focus on its core pharmaceutical interests.
POPULAR COMMENT THREADS
The Indian government is developing a system of medical device surveillance and adverse event reporting, dubbed the Materio-vigilance Programme of India.
Neuwave Medical roped in $25 million in equity funding to support development of its soft tissue ablation system, ramping up operations as it expands the reach for its innovative surgical system.
Boston Scientific revealed more details about its leadless pacemaker program, as it seeks to join Medtronic and St. Jude Medical in that market (which does not yet exist in the U.S., where the devices are still being investigated).
The FDA issued draft guidance this week on adaptive designs for medical device clinical studies. Similar to a prior guidance on the incorporation of patient preference data in clinical trials, the latest guidance should help companies perform trials faster, and signals greater flexibility on the behalf of the FDA.
Medtronic CEO Omar Ishrak has long turned to emerging markets as a potential growth driver, and tapping into India's burgeoning population will play a key role in ramping up the company's business there, he said.
Researchers have developed silicon chips that can be implanted in the brain and relay a person's intentions into the movement of robotic prosthetics.
From Our Sister Sites
A month ago, Amgen and AstraZeneca were confidently rolling up data from three highly touted late-stage studies on the psoriasis drug brodalumab for a new drug application that was widely viewed as a...
The speculation is building this week that Pfizer will either attempt another megadeal with GlaxoSmithKline or another run on AstraZeneca. Either would cut Pfizer's tax rate and give it some products to salve its various ills, lackluster stock price and poor performing portfolio. But the new thinking, like in the last 24 hours, is that smaller deals, perhaps a buyout of Shire or even Perrigo, or both, are better bets.